BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8372813)

  • 1. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia.
    Meyer S; Feremans W; Cantiniaux B; Capel P; Huygen K; Dicato M
    Am J Hematol; 1993 Aug; 43(4):307-9. PubMed ID: 8372813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b.
    Zhang X; Pan J; Guo J
    Acta Haematol; 2013; 130(1):44-6. PubMed ID: 23391844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
    Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
    Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
    Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
    J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
    Boussiotis VA; Pangalis GA
    Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic neutrophilic leukaemia.
    Bain BJ
    Acta Haematol; 2014; 131(1):45. PubMed ID: 24029118
    [No Abstract]   [Full Text] [Related]  

  • 11. Current Management of Chronic Neutrophilic Leukemia.
    Szuber N; Tefferi A
    Curr Treat Options Oncol; 2021 Jun; 22(7):59. PubMed ID: 34097138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.
    Kako S; Kanda Y; Sato T; Goyama S; Noda N; Shoda E; Oshima K; Inoue M; Izutsu K; Watanabe T; Motokura T; Chiba S; Fukayama M; Kurokawa M
    Am J Hematol; 2007 May; 82(5):386-90. PubMed ID: 17109389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic neutrophilic leukaemia.
    Gan GG; Pasagna JF; Eow GI; Nadarajan VS
    Singapore Med J; 2007 Mar; 48(3):e74-6. PubMed ID: 17342275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report).
    Nodarse-Cuní H; Iznaga-Marín N; Viera-Alvarez D; Rodríguez-Gómez H; Fernández-Fernández H; Blanco-López Y; Viada-González C; López-Saura P;
    J Laryngol Otol; 2004 Sep; 118(9):681-7. PubMed ID: 15517700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
    Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
    Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition of polycythemia vera to chronic neutrophilic leukemia.
    Higuchi T; Oba R; Endo M; Harada H; Mori H; Niikura H; Omine M; Fujita K
    Leuk Lymphoma; 1999 Mar; 33(1-2):203-6. PubMed ID: 10194140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
    J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.